eptifibatide
We examined markers of        thrombin generation and activity in patients enrolled in a randomized,       placebo-controlled, dose escalating trial of the platelet glycoprotein IIb-IIIa       inhibitor eptifibatide (Integrilintrade mark) administered concomitantly with       tissue plasminogen activator for the treatment of myocardial infarction.
We examined markers of        thrombin generation and activity in patients enrolled in a randomized,       placebo-controlled, dose escalating trial of the  @OBJECT$  @PREDICAT$  @SUBJECT$  (Integrilintrade mark) administered concomitantly with       tissue plasminogen activator for the treatment of myocardial infarction.